Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab 6 mg Extension Study in nAMD Patients
NCT03386474Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2018
- Primary completion
- Sep 2018
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of brolucizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Novartis. Started Jan 2018; status: completed.
02
Drugs
brolucizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03386474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03386474.